Market Access

Approval and demand tells you a product may be sold. Market access determines whether it will be. A product can be safe, effective and certified – and still fail because payers, users or, in case of MedTech, clinicians do not see enough value to adopt it. Stuart-Houghton Associates helps companies build a clear path from approval to real-world use.

Why it matters

Companies that leave access planning until after launch often face delays, lower prices or limited uptake.

Our services

• Early access planning – building payer requirements into development and study design.
• Stakeholder mapping – identifying who decides on adoption and reimbursement in each market.
• Value proposition development – clinical, economic and organisational benefits, clearly argued.
• Evidence planning – defining the data payers and providers will expect.
• Payer and provider engagement – materials and arguments for insurers, hospitals and buyers.
• Country-specific strategies – adapted to each local system.

An integrated view

Market access is inseparable from reimbursement, pricing and clinical acceptance. We address them together, and help you work with key opinion leaders, plan clinical evaluations and design training that supports adoption.

Our recommendations rest on thorough research into health systems, reimbursement mechanisms, competitors and published evidence, presented clearly for internal teams and external stakeholders.

The earlier access is considered, the better – ideally during development. But even after launch, a focused review can uncover barriers and unlock new opportunities.